Alzheimer’s Neuropsychiatric Symptoms Linked to CSF Amyloid and Protein Signatures

A cross-sectional analysis of 713 ADNI participants examined neuropsychiatric symptoms, cerebrospinal fluid amyloid-β42, cognition, and proteomic profiles. Several symptom domains were associated with lower amyloid-β42, while analyses highlighted heat shock proteins as candidates for further study.

Higher symptom burden was associated with lower CSF Aβ42.
Aβ42 partially mediated the symptom–cognition association.
Analyses implicated heat shock proteins in symptom-associated signatures.

Researchers analyzed data from 713 participants in the Alzheimer’s Disease Neuroimaging Initiative who had assessments of neuropsychiatric symptoms, cerebrospinal fluid (CSF) amyloid-β42 (Aβ42), proteomics, and cognition. Symptoms were assessed with the Neuropsychiatric Inventory Questionnaire and grouped into hyperactivity, psychosis, affective symptoms, and apathy. The cross-sectional study used regression and mediation analyses, proteomic network methods, and Mendelian randomization to investigate associations.

AI summary · Not yet editor-reviewed

Is this summary clinically accurate?

Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.

Source

BMC Medicine: Associations between neuropsychiatric symptoms and cerebrospinal fluid amyloid pathology, and convergent proteomic signatures in Alzheimer’s disease ↗

This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.